Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Pipeline-Prospector-Insert
    X

    Find drug development pipeline and deal Updates information

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type

              Companies

              Isofol Medical

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SPAIN Spain

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Annual Biomarkers Congress

              Participation Not Confirmed

              Request a Meeting Now

              The First Patient Included in Australia in Isofol's Phase 3 AGENT Study

              Contact the Supplier

              Lead Product(s): Arfolitixorin, Oxaliplatin, 5 Fluorouracil

              Therapeutic Area: Oncology

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 24, 2020

              Details:

              Isofol's drug candidate arfolitixorin is being evaluated in the first line of treatment of metastatic colorectal cancer (mCRC).

              PharmaMar

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SPAIN Spain

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Annual Biomarkers Congress

              Participation Not Confirmed

              Request a Meeting Now

              PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting...

              Contact the Supplier

              Lead Product(s): Lurbinectedin

              Therapeutic Area: Oncology

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Jazz Pharmaceuticals

              Deal Size: $1,000.0 million Upfront Cash: $200.0 million

              Deal Type: Licensing Agreement January 22, 2020

              Details:

              PharmaMar & Jazz signed an exclusive license agreement for U.S. rights to lurbinectedin, the effectiveness of which was subject to the expiration or early termination of the applicable HSR waiting period.

              PharmaCompass__DigitalAd